SMO Services and Solutions

About ClinPlus
Powered by Digital Intelligence
Empowering a New Paradigm in Clinical Research.

We attach great importance to the development and application of digital and intelligent technologies.

Our proprietary "Ruixing Clinical Trial Text Generation Algorithm" has been filed with the Cyberspace Administration of China (CAC).

Core Features of Ruixing Intelligent Management System
Business Operations Span Core Provinces and Cities Nationwide

As of June 30, 2026, we have undertaken over 4,700 SMO projects across China and overseas, participated in numerous high-profile domestic and international programs, and built extensive execution expertise — supporting the launch of 260+ products in domestic and global markets.

4,597
Total Employees in China
980+
Served Drug Clinical Trial Sites
200+
Cities Covered for Clinical Trials
4700+
Cumulative SMO Projects
Data as of June 30, 2026

The Company's primary clients are international pharmaceutical companies and well-known domestic innovative pharmaceutical companies. It has established partnerships with all of the top 10 global pharmaceutical companies of 2025. The Company provides clinical trial site management services to renowned domestic and international pharmaceutical companies and CROs, demonstrating outstanding service capabilities for high-quality innovative pharmaceutical companies. The SMO services it provides are characterized by high quality and efficiency, are at an advanced level within the industry, and conform to international standards.

Empowering Sponsors
  • Third-Party Audit
  • FSP Services
  • Database Services
  • Rapid Site Start-Up
  • Patient Education
  • Database Lock & Site Close-Out
  • Patient Recruitment
  • Modeling / Training
  • CRO Services
  • Patient Enrollment & Follow-Up Support
  • Site Feasibility Assessment
Empowering Research Sites
  • Trial Management
  • Site Promotion
  • Internal QC & GCP Training
  • Qualification / Credentialing Application
  • SOP Development & Technical Framework Establishment
  • Third-Party Audit or Audit Preparation
  • Site (Institution) Management

The Company's services span a wide range of areas, with significant competitive advantages established across multiple therapeutic areas, including hematologic malignancies, thoracic oncology, gastrointestinal oncology, cardiovascular diseases, urologic oncology, endocrine disorders, and infectious diseases.

Service Offerings

Clinical Trial Execution Strategy Modeling Service

ClinPlus's proprietary big data modeling system leverages performance big data from past projects to generate Site Selection Models, Start-Up Models, Enrollment Models, Risk Models, Quality Models, Data Models, and Patient & Investigator Cost Models, delivering precise execution strategies for clinical trials.

To date, ClinPlus's modeling data has been validated across 400+ SSU projects and 600+ enrollment projects, achieving match rates of 97.89% and 94.38% respectively against project plans — reducing the time required to build a clinical trial execution strategy from months to one week.

SSU Services

ClinPlus's SSU team covers key regions nationwide and is highly familiar with site processes. It anticipates potential obstacles and issues in project start-up, prepares contingency plans in advance, and mitigates them proactively.

Once the start-up plan is generated, ClinPlus's SSU services — combined with an innovative site activation platform — provide deeper interpretation of site requirements and analysis of clinical trial protocols. Multi-center essential documents can be generated with one click within the system, avoiding errors prone to manual document preparation and reducing time costs.

FSP Services

ClinPlus provides clients with more customized, professional, flexible, and sustainable FSP services.

Dual candidate sourcing channels (internal and external); a comprehensive training system; end-to-end management by a dedicated personnel team to improve workforce efficiency; and more diverse development opportunities for employees.

Drawing on a decade of professional experience focused on SMO services, ClinPlus has established long-term, stable FSP partnerships with numerous renowned research sites and sponsors — the longest of which has spanned over ten years.

ClinPlus Third-Party Quality Control & Audit Services

ClinPlus's QC team is deployed across core cities nationwide, professionally delivering research site audits, trial document audits, CAPA follow-up through closure, and consulting and training. We ensure that all clinical trial procedures comply with GCP, clinical trial protocols, relevant SOPs, and applicable laws and regulations — overseeing project execution to promptly identify and correct issues, safeguarding trial participants' rights and welfare, and ensuring that clinical trial data is scientific, authentic, and reliable with standard-compliant operations.

Inspection Meeting & Logistics Services

ClinPlus is well-versed in regulatory inspection procedures and professional meeting-logistics SOPs — achieving zero inspection-related withdrawals — and has developed a dedicated management SOP for inspection meeting logistics. With a convenient, coordinated network spanning 200+ cities, we precisely manage every detail and deliver full-process logistics support, upholding the rigor of inspection meetings and ensuring orderly reception for all parties.

By hosting these meetings, we free sponsors, hospitals, and investigators to focus on the inspection itself while easing preparation burdens. As with our SMO and patient recruitment services, we combine attention to detail, professionalism, and warmth — helping projects ensure quality and efficiency and advancing the high-quality development of pharmaceutical R&D.

Trial Participant Recruitment Services

ClinPlus has launched online services for trial participants and a proprietary trial participant recruitment mini-program, helping trial participants understand recruitment criteria faster and sign up for the trials they need.

We offer one-on-one online support from trial participant education specialists — trial participants with healthcare concerns or questions about clinical trials can connect directly with a ClinPlus trial participant education specialist.

The RuiXin Home new media platform regularly publishes recruitment notices, all vetted by an editorial team with clinical medicine and pharmacy backgrounds to deliver rigorous, professional, yet accessible education on disease-specific care, general health, and clinical trials.

Supporting the world's first-in-class PD-1/VEGF bispecific antibody

Backing the world's first approved EGFR/c-MET bispecific antibody

Enabling the world's first and only targeted therapy based on the innovative ABL myristoyl pocket (STAMP) mechanism

China's first approved and marketed oral GLP-1 drug

The world's first and currently only GIP/GLP-1 receptor agonist

China's first and currently only approved long-acting recombinant coagulation factor VIII

The world's first and currently only approved CLDN18.2-targeted therapy

China's first direct-acting oral anti-hepatitis C drug, sofosbuvir tablets, successfully launched

The world's first approved biologic for systemic lupus erythematosus (SLE), belimumab, launched

China's first domestically produced human papillomavirus (HPV) vaccine, Cecolin, successfully launched

Supported a client's world's first and only approved Trop-2-targeted ADC

The first domestically developed bispecific antibody and the world's first PD-1/CTLA-4 bispecific antibody

China's first and only CDK4/6 inhibitor approved for patients with early breast cancer

China's first approved selective JAK inhibitor for rheumatoid arthritis

China's first approved growth hormone product for Prader-Willi syndrome (PWS), among other innovative drugs approved and launched

Supported a client's world's first immuno-oncology drug approved for relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL)

The world's only highly selective small-peptide, monthly EPO receptor agonist for anemia in patients with non-dialysis chronic kidney disease

China's first CAR-T product for leukemia and for the treatment of graft-versus-host disease (GvHD)

China's first and currently only targeted therapy approved for leukemia — among other innovative drugs approved and launched

Helping multiple innovative drugs reach the market at home and abroad

Accelerate Digitalization
Enhance Management Efficiency →

We further upgraded our information systems to enhance employee output-value management and scientific workforce forecasting, and to strengthen cost control and refined personnel management. Our information management framework is certified to ISO27001, effectively safeguarding information and data security and ensuring the healthy, orderly, and sustainable development of our operations.
The invention patent "A Method for Determining Adverse Event Severity Grades, an Electronic Device, and a Storage Medium" has been issued a Notice of Grant of Invention Patent by the China National Intellectual Property Administration (CNIPA) — a breakthrough in information-technology innovation in the clinical research services sector.